检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:闫梅[1]
出 处:《临床医学进展》2022年第1期291-296,共6页Advances in Clinical Medicine
摘 要:目的:探讨利伐沙班对急性肺栓塞患者氧化应激及细胞因子的影响。方法:选取2020年1月到2021年8月收治的100例肺栓塞患者作为研究对象。随机分为对照组(n = 50)和观察组(n = 50)。对照组患者皮下注射低分子肝素钙联合口服华法林治疗,观察组患者采用皮下注射低分子肝素钙联合口服利伐沙班治疗。比较两组患者治疗4周后临床疗效,C反应蛋白(CRP)、白细胞介素-10 (IL-10)、肿瘤坏死因子-α (TNF-α)、丙二醛(MDA)及超氧化物歧化酶(SOD)水平。记录两组患者治疗期间不良反应发生情况。结果:治疗后观察组总有效率高于对照组。两组肺栓塞患者血清SOD水平治疗后较治疗前均增高,MDA水平均下降,差异均有统计学意义(P 0.05)。治疗后两组肺栓塞患者血清IL-10、CRP、TNF-α水平较治疗前均下降,且观察组患者血清IL-10、CRP、TNF-α水平低于对照组,差异均有统计学意义(P 0.05)。结论:利伐沙班治疗急性肺栓塞患者疗效确切,可有效抑制炎症反应,安全性较好。但利伐沙班和华法林在抗氧化应激方面没有显著差异。Objective: To observe the effect of rivaroxaban on oxidative stress and cytokine in patients with acute pulmonary embolism. Methods: A total of 100 patients with acute pulmonary embolism were selected from January 2020 to August 2021, and they were randomly divided into control group and observation group, each of 50 cases. Patients in control group received low molecular-weight heparin combined with warfarin, while patients in observation group received low-molecular-weight heparin combined with rivaroxaban. The total effective rate, C reactive protein (CRP), interleukin-10 (IL-10) and tumor necrosis factor-α (TNF-α), malondialdehyde (MDA) and oxide dismutase (SOD) in serum levels before and after four weeks of treatment were compared between the two groups. The incidence of adverse reactions was observed during the treatment. Results: Clinical effect in observation group was statistically significantly better than that in control group (P 0.05). After treatment, the levels of serum IL-10, CRP and TNF-α in patients with pulmonary embolism in the two groups decreased, and the levels of serum IL-10, CRP and TNF-α in the observation group were lower than those in the control group (P 0.05). Conclusion: Rivaroxaban is effective in the treatment of acute pulmonary embolism, which can effectively inhibit inflammatory reaction, and safety is relatively higher. There is no significant difference in antioxidant stress between rivaroxaban and warfarin.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3